“Our data is clinical data, considered the most important asset for large pharmaceutical companies. […] They want to control precisely what they write and how they write it. This is a big issue for Yseop.”
Yseop was featured in Forbes' latest article on "The Promise and Challenge of Deploying AI in Clinical Trials." Emmanuel Walckenaer, Managing Director of Yseop, was able to look back on the activity of this innovative SME.
Yseop, participation supported by Grégoire Sentilhes, Michaël Strauss-Kahn and Gaëtan Leenhardt, is one of the world leaders in Generative Artificial Intelligence (Generative AI) for regulated industries, particularly pharmaceuticals.
Yseop's SaaS solution makes it possible to transform complex data into natural language, by automating business rules and respecting the reliability and traceability requirements of demanding processes such as the documentary chain for marketing new drugs, clinical studies , financial reports... which are key elements for regulated industries and its clients such as Sanofi, Eli Lily, GSK and Novartis.
By 2023, Yseop has generated more than 10 reports on more than 000 trials and eliminated tens of thousands of hours of writing and review, as Emmanuel Walckenaer explains: "It takes on average 150 weeks between database lock data and submission. We want to bring about acceleration. »
These savings represent potential acceleration for the introduction of new medicines to the market and reinforce Yseop's commitment to bringing life-saving medicines to patients more quickly.
